Please enable JavaScript to continue using this application.

Compare $ARCT vs $CCCC | Chartloom

Compare

$ARCT vs $CCCC

Arcturus Therapeutics Holdings Inc · C4 Therapeutics, Inc

ARCT

Arcturus Therapeutics Holdings Inc

CCCC

C4 Therapeutics, Inc

Compare $ARCT vs $CCCC

Comparing Arcturus Therapeutics Holdings Inc and C4 Therapeutics, Inc

ARCTArcturus Therapeutics Holdings Inc

CCCCC4 Therapeutics, Inc

ARCTArcturus Therapeutics Holdings Inc

Market cap

$390M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.64x

Rev growth (TTM)

-76.0%

YTD performance

119.8%

52W performance

-35.2%

FCF yield

-18.7%

CCCCC4 Therapeutics, Inc

Market cap

$349M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

15.01x

Rev growth (TTM)

2.3%

YTD performance

63.7%

52W performance

41.7%

FCF yield

-24.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ARCT

CCCC

Detailed metrics comparison

ARCT

Arcturus Therapeutics Holdings Inc

CCCC

C4 Therapeutics, Inc

Market Cap

ARCT$390M

CCCC$349M

Enterprise Value

ARCT$199M

CCCC$271M

Price

ARCT$13.74

CCCC$3.16

P/E Ratio

ARCTN/A

CCCCN/A

P/S Ratio

ARCT13.30x

CCCC9.97x

EV/Sales

ARCT6.78x

CCCC7.73x

EV/EBITDA

ARCT1.82x

CCCC0.00x

P/B Ratio

ARCT2.16x

CCCC1.47x

P/FCF Ratio

ARCTN/A

CCCCN/A

EV/FCF

ARCT-2.73x

CCCC-3.17x

PEG Ratio

ARCTN/A

CCCCN/A

Forward P/E (NTM)

ARCTN/A

CCCCN/A

Forward P/S (NTM)

ARCT21.64x

CCCC15.01x

Revenue (TTM)

ARCT$29M

CCCC$35M

Revenue Growth (YoY)

ARCT-76.0%

CCCC2.3%

Forward Rev Growth

ARCT107.7%

CCCC-15.9%

Gross Margin (TTM)

ARCT0.0%

CCCC0.0%

Operating Margin (TTM)

ARCT0.0%

CCCC0.0%

EBITDA Margin (TTM)

ARCT-339.0%

CCCC-283.8%

Net Margin (TTM)

ARCT-317.6%

CCCC-289.4%

FCF Margin (TTM)

ARCT-248.6%

CCCC-243.7%

Net Income (TTM)

ARCT$-93M

CCCC$-101M

FCF (TTM)

ARCT$-73M

CCCC$-85M

EPS (TTM)

ARCT-$3.28

CCCC-$0.78

ROE (TTM)

ARCT-4654.0%

CCCC-4545.0%

ROA (TTM)

ARCT-3646.0%

CCCC-3090.0%

ROIC (TTM)

ARCT-4654.0%

CCCC-4545.0%

Cash

ARCT$191M

CCCC$79M

Debt

ARCT$0

CCCC$0

Net Cash/Debt

ARCT$191M

CCCC$79M

Current Ratio (TTM)

ARCT5.88x

CCCC5.45x

Quick Ratio (TTM)

ARCT5.76x

CCCC5.29x

Debt/Equity (TTM)

ARCT0.00x

CCCC0.00x

Debt/Assets (TTM)

ARCT0.0%

CCCC0.0%

Interest Coverage (TTM)

ARCTN/A

CCCCN/A

Net Debt/EBITDA (TTM)

ARCT0.00x

CCCC0.00x

Beta

ARCT2.60

CCCC3.16

52W Performance

ARCT-35.2%

CCCC41.7%

YTD Performance

ARCT119.8%

CCCC63.7%

% from 52W High

ARCT-43.2%

CCCC-38.9%

% from 52W Low

ARCT149.8%

CCCC87.0%

Asset Turnover (TTM)

ARCT0.11x

CCCC0.11x

FCF Yield (TTM)

ARCT-18.7%

CCCC-24.4%

Earnings Yield (TTM)

ARCT-23.9%

CCCC-29.0%

Dividend Yield (TTM)

ARCTN/A

CCCCN/A

Rule of 40

ARCT-324.5

CCCC-241.4

EV/GP/RG

ARCTN/A

CCCCN/A

Ticker research

View ARCT research View CCCC research

Metric	ARCT Arcturus Therapeutics Holdings Inc	CCCC C4 Therapeutics, Inc
Market & Valuation
Market Cap	$390M	$349M
Enterprise Value	$199M	$271M
Price	$13.74	$3.16
P/E Ratio	N/A	N/A
P/S Ratio	13.30x	9.97x
EV/Sales	6.78x	7.73x
EV/EBITDA	1.82x	0.00x
P/B Ratio	2.16x	1.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.73x	-3.17x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.64x	15.01x
Revenue & Growth
Revenue (TTM)	$29M	$35M
Revenue Growth (YoY)	-76.0%	2.3%
Forward Rev Growth	107.7%	-15.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-339.0%	-283.8%
Net Margin (TTM)	-317.6%	-289.4%
FCF Margin (TTM)	-248.6%	-243.7%
Net Income (TTM)	$-93M	$-101M
FCF (TTM)	$-73M	$-85M
EPS (TTM)	-$3.28	-$0.78
ROE (TTM)	-4654.0%	-4545.0%
ROA (TTM)	-3646.0%	-3090.0%
ROIC (TTM)	-4654.0%	-4545.0%
Financial Health
Cash	$191M	$79M
Debt	$0	$0
Net Cash/Debt	$191M	$79M
Current Ratio (TTM)	5.88x	5.45x
Quick Ratio (TTM)	5.76x	5.29x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	3.16
52W Performance	-35.2%	41.7%
YTD Performance	119.8%	63.7%
% from 52W High	-43.2%	-38.9%
% from 52W Low	149.8%	87.0%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.11x
FCF Yield (TTM)	-18.7%	-24.4%
Earnings Yield (TTM)	-23.9%	-29.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-324.5	-241.4
EV/GP/RG	N/A	N/A
Ticker research	View ARCT research	View CCCC research

Valuation

P/S Ratio

CCCC

9.97x

ARCT

13.30x

EV/FCF

CCCC

-3.17x

ARCT

-2.73x

Growth & revenue

Revenue Growth TTM

CCCC

2.3%

ARCT

-76.0%

Forward Revenue Growth

ARCT

107.7%

CCCC

-15.9%

Profitability & performance

Gross Margin

ARCT

0.0%

CCCC

0.0%

ROE

CCCC

-4545.0%

ARCT

-4654.0%

FCF Yield %

ARCT

-18.7%

CCCC

-24.4%

52-Week Performance

CCCC

41.7%

ARCT

-35.2%

Detailed metrics comparison

ARCT

Arcturus Therapeutics Holdings Inc

CCCC

C4 Therapeutics, Inc

Market Cap

ARCT$390M

CCCC$349M

Enterprise Value

ARCT$199M

CCCC$271M

Price

ARCT$13.74

CCCC$3.16

P/E Ratio

ARCTN/A

CCCCN/A

P/S Ratio

ARCT13.30x

CCCC9.97x

EV/Sales

ARCT6.78x

CCCC7.73x

EV/EBITDA

ARCT1.82x

CCCC0.00x

P/B Ratio

ARCT2.16x

CCCC1.47x

P/FCF Ratio

ARCTN/A

CCCCN/A

EV/FCF

ARCT-2.73x

CCCC-3.17x

PEG Ratio

ARCTN/A

CCCCN/A

Forward P/E (NTM)

ARCTN/A

CCCCN/A

Forward P/S (NTM)

ARCT21.64x

CCCC15.01x

Revenue (TTM)

ARCT$29M

CCCC$35M

Revenue Growth (YoY)

ARCT-76.0%

CCCC2.3%

Forward Rev Growth

ARCT107.7%

CCCC-15.9%

Gross Margin (TTM)

ARCT0.0%

CCCC0.0%

Operating Margin (TTM)

ARCT0.0%

CCCC0.0%

EBITDA Margin (TTM)

ARCT-339.0%

CCCC-283.8%

Net Margin (TTM)

ARCT-317.6%

CCCC-289.4%

FCF Margin (TTM)

ARCT-248.6%

CCCC-243.7%

Net Income (TTM)

ARCT$-93M

CCCC$-101M

FCF (TTM)

ARCT$-73M

CCCC$-85M

EPS (TTM)

ARCT-$3.28

CCCC-$0.78

ROE (TTM)

ARCT-4654.0%

CCCC-4545.0%

ROA (TTM)

ARCT-3646.0%

CCCC-3090.0%

ROIC (TTM)

ARCT-4654.0%

CCCC-4545.0%

Cash

ARCT$191M

CCCC$79M

Debt

ARCT$0

CCCC$0

Net Cash/Debt

ARCT$191M

CCCC$79M

Current Ratio (TTM)

ARCT5.88x

CCCC5.45x

Quick Ratio (TTM)

ARCT5.76x

CCCC5.29x

Debt/Equity (TTM)

ARCT0.00x

CCCC0.00x

Debt/Assets (TTM)

ARCT0.0%

CCCC0.0%

Interest Coverage (TTM)

ARCTN/A

CCCCN/A

Net Debt/EBITDA (TTM)

ARCT0.00x

CCCC0.00x

Beta

ARCT2.60

CCCC3.16

52W Performance

ARCT-35.2%

CCCC41.7%

YTD Performance

ARCT119.8%

CCCC63.7%

% from 52W High

ARCT-43.2%

CCCC-38.9%

% from 52W Low

ARCT149.8%

CCCC87.0%

Asset Turnover (TTM)

ARCT0.11x

CCCC0.11x

FCF Yield (TTM)

ARCT-18.7%

CCCC-24.4%

Earnings Yield (TTM)

ARCT-23.9%

CCCC-29.0%

Dividend Yield (TTM)

ARCTN/A

CCCCN/A

Rule of 40

ARCT-324.5

CCCC-241.4

EV/GP/RG

ARCTN/A

CCCCN/A

Ticker research

View ARCT research View CCCC research

Metric	ARCT Arcturus Therapeutics Holdings Inc	CCCC C4 Therapeutics, Inc
Market & Valuation
Market Cap	$390M	$349M
Enterprise Value	$199M	$271M
Price	$13.74	$3.16
P/E Ratio	N/A	N/A
P/S Ratio	13.30x	9.97x
EV/Sales	6.78x	7.73x
EV/EBITDA	1.82x	0.00x
P/B Ratio	2.16x	1.47x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.73x	-3.17x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	21.64x	15.01x
Revenue & Growth
Revenue (TTM)	$29M	$35M
Revenue Growth (YoY)	-76.0%	2.3%
Forward Rev Growth	107.7%	-15.9%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-339.0%	-283.8%
Net Margin (TTM)	-317.6%	-289.4%
FCF Margin (TTM)	-248.6%	-243.7%
Net Income (TTM)	$-93M	$-101M
FCF (TTM)	$-73M	$-85M
EPS (TTM)	-$3.28	-$0.78
ROE (TTM)	-4654.0%	-4545.0%
ROA (TTM)	-3646.0%	-3090.0%
ROIC (TTM)	-4654.0%	-4545.0%
Financial Health
Cash	$191M	$79M
Debt	$0	$0
Net Cash/Debt	$191M	$79M
Current Ratio (TTM)	5.88x	5.45x
Quick Ratio (TTM)	5.76x	5.29x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	3.16
52W Performance	-35.2%	41.7%
YTD Performance	119.8%	63.7%
% from 52W High	-43.2%	-38.9%
% from 52W Low	149.8%	87.0%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.11x
FCF Yield (TTM)	-18.7%	-24.4%
Earnings Yield (TTM)	-23.9%	-29.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-324.5	-241.4
EV/GP/RG	N/A	N/A
Ticker research	View ARCT research	View CCCC research